HRP20201257T1 - Liposomi za tretman virusnih infekcija - Google Patents
Liposomi za tretman virusnih infekcija Download PDFInfo
- Publication number
- HRP20201257T1 HRP20201257T1 HRP20201257TT HRP20201257T HRP20201257T1 HR P20201257 T1 HRP20201257 T1 HR P20201257T1 HR P20201257T T HRP20201257T T HR P20201257TT HR P20201257 T HRP20201257 T HR P20201257T HR P20201257 T1 HRP20201257 T1 HR P20201257T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- empty
- empty liposome
- virus
- infection
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims 35
- 230000009385 viral infection Effects 0.000 title claims 11
- 208000036142 Viral infection Diseases 0.000 title claims 9
- 239000000203 mixture Substances 0.000 claims 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 24
- 235000012000 cholesterol Nutrition 0.000 claims 12
- 208000015181 infectious disease Diseases 0.000 claims 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 3
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 201000006082 Chickenpox Diseases 0.000 claims 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 241000701027 Human herpesvirus 6 Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000030156 Marburg disease Diseases 0.000 claims 1
- 241001115401 Marburgvirus Species 0.000 claims 1
- 206010046980 Varicella Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Sastav koji obuhvaća, poželjno se sastoji od,
(i) pojedinog praznog liposoma, naznačenog time da je naveden pojedini prazni liposom odabran od
(a) praznog liposoma koji se sastoji od sfingomijelina i kolesterola, pri čemu je količina kolesterola barem 20% (masenog udjela); ili
(b) praznog liposoma koji se sastoji od sfingomijelina;
ili
(ii) mješavine praznih liposoma; naznačene time da navedena mješavina praznih liposoma obuhvaća
(a) prvi prazan liposom koji se sastoji od sfingomijelina i kolesterola, pri čemu je količina kolesterola barem 20% (masenog udjela); i
(b) drugi prazan liposom koji se sastoji od sfingomijelina;
za korištenje u metodi tretiranja ili prevencije virusne infekcije kod sisavaca, poželjno kod ljudi.
2. Sastav za korištenje prema zahtjevu 1, naznačen time da naveden sastav obuhvaća, poželjno se sastoji od, pojedinog praznog liposoma, naznačen time da je naveden pojedini prazni liposom prazni liposom koji se sastoji od sfingomijelina i kolesterola, pri čemu je količina kolesterola barem 20% (masenog udjela).
3. Sastav za korištenje prema zahtjevu 1, naznačen time da naveden sastav obuhvaća, poželjno se sastoji od, mješavine praznih liposoma, naznačen time da navedena mješavina praznih liposoma obuhvaća (a) prvi prazan liposom koji se sastoji od sfingomijelina i kolesterola, pri čemu je količina kolesterola barem 20% (masenog udjela); i (b) drugi prazan liposom koji se sastoji od sfingomijelina.
4. Sastav za korištenje prema bilo kojem od zahtjeva 1 do 3, naznačen time da je količina kolesterola navedenog praznog liposoma 20% - 70% (masenog udjela), i pri čemu je poželjna količina kolesterola naveenog praznog liposoma 25% - 60% (masenog udjela).
5. Sastav za korištenje prema bilo kojem od zahtjeva 1 do 4, naznačen time da je količina kolesterola navedenog praznog liposoma 45% - 55% (masenog udjela), i pri čemu je poželjna količina kolesterola navedenog praznog liposoma oko 50% (masenog udjela).
6. Sastav za korištenje prema bilo kojem od zahtjeva 1 do 5, naznačen time da navedena mješavina praznih liposoma obuhvaća barem 30% (masenog udjela) navedenog prvog praznog liposoma i najviše 70% (masenog udjela) navedenog drugog praznog liposoma, i pri čemu poželjno navedena mješavina praznih liposoma obuhvaća barem 40% (masenog udjela) navedenog prvog praznog liposoma i najviše 60% (masenog udjela) navedenog drugog praznog liposoma.
7. Sastav za korištenje prema bilo kojem od zahtjeva 1 do 6, naznačen time da navedena mješavina praznih liposoma obuhvaća barem 45% (masenog udjela) navedenog prvog praznog liposoma i najviše 55% (masenog udjela) navedenog drugog praznog liposoma, i pri čemu poželjno navedena mješavina praznih liposoma obuhvaća oko 50% (masenog udjela) navedenog prvog praznog liposoma i oko 50% (masenog udjela) navedenog drugog praznog liposoma.
8. Sastav za korištenje prema zahtjevu 1, naznačen time da naveden sastav obuhvaća, poželjno se sastoji od, pojedinog praznog liposoma, naznačen time da je naveden pojedini prazni liposom prazni liposom koji se sastoji od sfingomijelina.
9. Sastav za korištenje prema bilo kojem od zahtjeva 1 do 8, naznačen time da je virusna infekcija infekcija uzrokovana virusom s ovojnicom.
10. Sastav za korištenje prema zahtjevu 9, naznačen time da je naveden virus s ovojnicom odabran od virusa hepatitisa C (HCV), virusa humane imunodeficijencije (HIV), T–limfotropnog virusa, herpes virusa, virusa ospica, virusa vodenih kozica, virusa gripe, virusa Ebole ili virusa Marburg.
11. Sastav za korištenje prema bilo kojem od zahtjeva 1 do 8, naznačen time da je navedena virusna infekcija infekcija virusom hepatitisa C.
12. Sastav za korištenje prema bilo kojem od zahtjeva 1 do 8, naznačen time da je navedena virusna infekcija infekcija virusom humane imunodeficijencije (HIV), i pri čemu je poželjno navedena virusna infekcija infekcija virusom humane imunodeficijencije tip 1 (HIV-1).
13. Sastav za korištenje prema bilo kojem od zahtjeva 1 do 8, naznačen time da je navedena virusna infekcija infekcija herpes virusom, pri čemu je poželjno navedena infekcija herpes virusom infekcija virusa herpes simpleks tip 1 (HSV-1) ili infekcija humanog herpes virusa tip 6 (HHV6).
14. Sastav za korištenje prema bilo kojem od zahtjeva 1 do 8, naznačen time da je navedena virusna infekcija infekcija virusom gripe ili infekcija virusom ospica.
15. Sastav za korištenje prema bilo kojem od zahtjeva 1 do 8, naznačen time da je navedena virusna infekcija infekcija virusom Ebole ili infekcija virusom Marburg.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16174700 | 2016-06-16 | ||
EP17731852.4A EP3471732B1 (en) | 2016-06-16 | 2017-06-15 | Liposomes for the treatment of viral infections |
PCT/EP2017/064653 WO2017216282A1 (en) | 2016-06-16 | 2017-06-15 | Liposomes for the treatment of viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201257T1 true HRP20201257T1 (hr) | 2020-11-13 |
Family
ID=56134203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201257TT HRP20201257T1 (hr) | 2016-06-16 | 2020-08-11 | Liposomi za tretman virusnih infekcija |
Country Status (12)
Country | Link |
---|---|
US (2) | US20190328663A1 (hr) |
EP (1) | EP3471732B1 (hr) |
DK (1) | DK3471732T3 (hr) |
ES (1) | ES2811025T3 (hr) |
HR (1) | HRP20201257T1 (hr) |
HU (1) | HUE049939T2 (hr) |
LT (1) | LT3471732T (hr) |
PL (1) | PL3471732T3 (hr) |
PT (1) | PT3471732T (hr) |
RS (1) | RS60602B1 (hr) |
SI (1) | SI3471732T1 (hr) |
WO (1) | WO2017216282A1 (hr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015084677A1 (en) | 2013-12-02 | 2015-06-11 | Arytha Biosciences, Llc | Toxoid preparation and uses thereof |
WO2019202101A1 (en) | 2018-04-20 | 2019-10-24 | Combioxin Sa | Treatment of sepsis and septic shock |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007252967B2 (en) * | 2006-05-19 | 2011-11-10 | Viroblock S.A. | A composition for inactivating an enveloped virus |
CN109549925B (zh) | 2012-06-14 | 2022-06-17 | 伯尔尼大学 | 用于治疗细菌感染的定制脂质体 |
-
2017
- 2017-06-15 PL PL17731852T patent/PL3471732T3/pl unknown
- 2017-06-15 ES ES17731852T patent/ES2811025T3/es active Active
- 2017-06-15 US US16/310,319 patent/US20190328663A1/en not_active Abandoned
- 2017-06-15 SI SI201730343T patent/SI3471732T1/sl unknown
- 2017-06-15 LT LTEP17731852.4T patent/LT3471732T/lt unknown
- 2017-06-15 HU HUE17731852A patent/HUE049939T2/hu unknown
- 2017-06-15 EP EP17731852.4A patent/EP3471732B1/en active Active
- 2017-06-15 WO PCT/EP2017/064653 patent/WO2017216282A1/en unknown
- 2017-06-15 DK DK17731852.4T patent/DK3471732T3/da active
- 2017-06-15 PT PT177318524T patent/PT3471732T/pt unknown
- 2017-06-15 RS RS20200872A patent/RS60602B1/sr unknown
-
2020
- 2020-08-11 HR HRP20201257TT patent/HRP20201257T1/hr unknown
-
2022
- 2022-09-20 US US17/948,713 patent/US20230028179A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PL3471732T3 (pl) | 2020-10-19 |
SI3471732T1 (sl) | 2020-09-30 |
PT3471732T (pt) | 2020-08-24 |
EP3471732A1 (en) | 2019-04-24 |
RS60602B1 (sr) | 2020-08-31 |
HUE049939T2 (hu) | 2020-11-30 |
US20230028179A1 (en) | 2023-01-26 |
DK3471732T3 (da) | 2020-08-17 |
LT3471732T (lt) | 2020-09-10 |
ES2811025T3 (es) | 2021-03-10 |
WO2017216282A1 (en) | 2017-12-21 |
EP3471732B1 (en) | 2020-05-13 |
US20190328663A1 (en) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201257T1 (hr) | Liposomi za tretman virusnih infekcija | |
CY1124756T1 (el) | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας | |
CO6460701A2 (es) | Métodos y composiciones para inmunización contra virus | |
BR112022004424A2 (pt) | Pró-fármacos antivirais e formulações dos mesmos | |
EA202092117A1 (ru) | Терапевтические композиции 4'-галогенсодержащих нуклеотидов и нуклеозидов и их применение | |
CO2017007619A2 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
WO2016100807A3 (en) | Human antibodies to influenza hemagglutinin | |
BR112018076913A2 (pt) | fosforamidatos para o tratamento do vírus da hepatite b | |
JP2017524339A5 (hr) | ||
MX2015005500A (es) | Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer. | |
BR112019005205A2 (pt) | composto de di-hidropirimidina e método de preparação e uso do mesmo | |
EA201890196A1 (ru) | Композиция для устранения заложенности носа, обладающая противовирусным действием | |
WO2009094190A3 (en) | Methods of treating viral infections | |
BR112013002296A2 (pt) | composição farmacêutica e respectivo uso e método para tratar doença infecciosa | |
UY38755A (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
CL2023000383A1 (es) | Profármacos de análogos de nucleótidos de fosfonamida y su uso farmacéutico | |
WO2016195522A3 (en) | Antiviral composition | |
BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
PH12020551051A1 (en) | Human antibodies to influenza hemagglutinin | |
WO2016025010A8 (en) | A novel broad-spectrum antiviral synergistic pharmaceutical composition for the treatment and prevention of viral infections | |
BR112017000543A2 (pt) | agentes para o tratamento de doenças infecciosas retrovirais | |
EA202191220A1 (ru) | НОВЫЕ МОЧЕВИНО-6,7-ДИГИДРО-4H-ПИРАЗОЛО[4,3-с]ПИРИДИНЫ, АКТИВНЫЕ ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) | |
BR112019017855A8 (pt) | Compostos, composição farmacêutica compreendendo os ditos compostos, usos dos mesmos para tratar o vírus da hepatite b e o vírus da imunodeficiência humana e processo para a preparação dos ditos compostos | |
WO2018056528A3 (ko) | 인플루엔자 b 백신 | |
EA201990528A1 (ru) | Дигидропиримидиновые соединения и способ их получения и применения |